• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

选择性雄激素受体调节剂 (SARM) 治疗骨质疏松雌性大鼠的影响。

Effects of selective androgen receptor modulator (SARM) treatment in osteopenic female rats.

机构信息

College of Pharmacy, Division of Pharmaceutics, The Ohio State University, Columbus, Ohio 43210, USA.

出版信息

Pharm Res. 2009 Nov;26(11):2471-7. doi: 10.1007/s11095-009-9962-7. Epub 2009 Sep 1.

DOI:10.1007/s11095-009-9962-7
PMID:19728047
Abstract

PURPOSE

Although androgens are known to protect bone, side effects and poor oral bioavailability have limited their use. We previously reported that S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide (S-4) is a potent and tissue-selective androgen receptor modulator (SARM). This study was designed to evaluate the skeletal effects of S-4 in an osteopenic model.

METHODS

Aged female rats were gonadectomized or sham operated on day 1 and assigned to treatment groups. Dosing was initiated on day 90 and continued daily until day 210. Whole animal bone mineral density (BMD), body weight, and fat mass were determined by dual energy x-ray absorptiometry (DEXA). Regional analysis of excised bones was performed using DEXA or computed tomography. Femur strength was evaluated by 3-point bending.

RESULTS

S-4 restored whole body and lumbar vertebrae (L5-L6) BMD to the level of intact controls. Significant increases in cortical bone quality were observed at the femoral midshaft, resulting in increased load bearing capacity.

CONCLUSIONS

S-4 demonstrated partial/complete recovery of bone parameters to age-matched intact levels. Increased efficacy observed in cortical bone sites is consistent with reported androgen action in bone. The ability of S-4 to promote bone anabolism, prevent bone resorption, and increase skeletal muscle mass/strength positions these drugs as promising new alternatives for the treatment of osteoporosis.

摘要

目的

尽管雄激素已知可保护骨骼,但由于副作用和较差的口服生物利用度,其应用受到限制。我们之前报道过 S-3-(4-乙酰氨基-苯氧基)-2-羟基-2-甲基-N-(4-硝基-3-三氟甲基-苯)-丙酰胺(S-4)是一种有效的组织选择性雄激素受体调节剂(SARM)。本研究旨在评估 S-4 在骨质疏松模型中的骨骼作用。

方法

雌性大鼠在第 1 天去势或假手术,并分配至治疗组。第 90 天开始给药,每天持续给药直至第 210 天。双能 X 射线吸收仪(DEXA)测定全身骨密度(BMD)、体重和体脂量。使用 DEXA 或计算机断层扫描对切除的骨骼进行局部分析。股骨强度通过三点弯曲试验进行评估。

结果

S-4 将全身和腰椎(L5-L6)BMD 恢复至完整对照组的水平。在股骨中段观察到皮质骨质量的显著增加,导致承载能力增加。

结论

S-4 使骨参数部分/完全恢复至与年龄匹配的完整水平。在皮质骨部位观察到的更高疗效与雄激素在骨骼中的作用一致。S-4 促进骨合成、防止骨吸收和增加骨骼肌量/强度的能力使这些药物成为治疗骨质疏松症的有前途的新选择。

相似文献

1
Effects of selective androgen receptor modulator (SARM) treatment in osteopenic female rats.选择性雄激素受体调节剂 (SARM) 治疗骨质疏松雌性大鼠的影响。
Pharm Res. 2009 Nov;26(11):2471-7. doi: 10.1007/s11095-009-9962-7. Epub 2009 Sep 1.
2
Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats.选择性雄激素受体调节剂治疗可改善去势大鼠的肌肉力量和身体成分,并预防骨质流失。
Endocrinology. 2005 Nov;146(11):4887-97. doi: 10.1210/en.2005-0572. Epub 2005 Aug 11.
3
Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats.选择性雄激素受体调节剂(SARM)治疗可预防去卵巢大鼠的骨质流失并减少体脂。
Pharm Res. 2007 Feb;24(2):328-35. doi: 10.1007/s11095-006-9152-9. Epub 2006 Oct 25.
4
Prostaglandin E2 increases bone strength in intact rats and in ovariectomized rats with established osteopenia.前列腺素E2可增强正常大鼠以及已患骨质减少的去卵巢大鼠的骨强度。
Bone. 1998 Sep;23(3):249-55. doi: 10.1016/s8756-3282(98)00102-1.
5
The novel non-steroidal selective androgen receptor modulator S-101479 has additive effects with bisphosphonate, selective estrogen receptor modulator, and parathyroid hormone on the bones of osteoporotic female rats.新型非甾体选择性雄激素受体调节剂 S-101479 与双膦酸盐、选择性雌激素受体调节剂和甲状旁腺激素在骨质疏松雌性大鼠的骨骼上具有相加作用。
Biol Pharm Bull. 2012;35(7):1096-104. doi: 10.1248/bpb.b12-00054.
6
Raloxifene and teriparatide (hPTH 1-34) have complementary effects on the osteopenic skeleton of ovariectomized rats.雷洛昔芬和特立帕肽(人甲状旁腺激素1-34)对去卵巢大鼠的骨质减少骨骼具有互补作用。
J Bone Miner Metab. 2005;23 Suppl:62-8. doi: 10.1007/BF03026325.
7
Combination treatment with a selective androgen receptor modulator q(SARM) and a bisphosphonate has additive effects in osteopenic female rats.
J Bone Miner Res. 2009 Feb;24(2):231-40. doi: 10.1359/jbmr.081007.
8
A comparative study of the bone metabolic response to dried plum supplementation and PTH treatment in adult, osteopenic ovariectomized rat.干梅补充剂和 PTH 治疗对成年骨质疏松去卵巢大鼠骨代谢反应的比较研究。
Bone. 2014 Jan;58:151-9. doi: 10.1016/j.bone.2013.10.005. Epub 2013 Oct 11.
9
A nonprostanoid EP4 receptor selective prostaglandin E2 agonist restores bone mass and strength in aged, ovariectomized rats.一种非前列腺素EP4受体选择性前列腺素E2激动剂可恢复老年去卵巢大鼠的骨量和骨强度。
J Bone Miner Res. 2006 Apr;21(4):565-75. doi: 10.1359/jbmr.051110. Epub 2006 Apr 5.
10
Pharmacokinetics of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro- 3-trifluoromethyl-phenyl)-propionamide in rats, a non-steroidal selective androgen receptor modulator.非甾体选择性雄激素受体调节剂S-3-(4-乙酰氨基苯氧基)-2-羟基-2-甲基-N-(4-硝基-3-三氟甲基苯基)丙酰胺在大鼠体内的药代动力学
Xenobiotica. 2004 Mar;34(3):273-80. doi: 10.1080/0049825041008962.

引用本文的文献

1
The role of androgens and global and tissue-specific androgen receptor expression on body composition, exercise adaptation, and performance.雄激素以及整体和组织特异性雄激素受体表达在身体成分、运动适应和运动表现方面的作用。
Biol Sex Differ. 2025 Apr 23;16(1):28. doi: 10.1186/s13293-025-00707-6.
2
A molecular switch from tumor suppressor to oncogene in ER+ve breast cancer: Role of androgen receptor, JAK-STAT, and lineage plasticity.在 ER+ve 乳腺癌中,一种从肿瘤抑制因子到癌基因的分子开关:雄激素受体、JAK-STAT 和谱系可塑性的作用。
Proc Natl Acad Sci U S A. 2024 Oct;121(40):e2406837121. doi: 10.1073/pnas.2406837121. Epub 2024 Sep 23.
3

本文引用的文献

1
Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats.选择性雄激素受体调节剂(SARM)治疗可预防去卵巢大鼠的骨质流失并减少体脂。
Pharm Res. 2007 Feb;24(2):328-35. doi: 10.1007/s11095-006-9152-9. Epub 2006 Oct 25.
2
Pharmacokinetics of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro- 3-trifluoromethyl-phenyl)-propionamide in rats, a non-steroidal selective androgen receptor modulator.非甾体选择性雄激素受体调节剂S-3-(4-乙酰氨基苯氧基)-2-羟基-2-甲基-N-(4-硝基-3-三氟甲基苯基)丙酰胺在大鼠体内的药代动力学
Xenobiotica. 2004 Mar;34(3):273-80. doi: 10.1080/0049825041008962.
3
Selective androgen receptor modulator use and related adverse events including drug-induced liver injury: Analysis of suspected cases.
选择性雄激素受体调节剂的使用及相关不良事件,包括药物性肝损伤:疑似病例分析。
Eur J Clin Pharmacol. 2024 Feb;80(2):185-202. doi: 10.1007/s00228-023-03592-3. Epub 2023 Dec 7.
4
Effects of ligandrol as a selective androgen receptor modulator in a rat model for osteoporosis.激动剂在骨质疏松大鼠模型中作为选择性雄激素受体调节剂的作用。
J Bone Miner Metab. 2023 Nov;41(6):741-751. doi: 10.1007/s00774-023-01453-8. Epub 2023 Jul 6.
5
Treatment of osteoporosis using a selective androgen receptor modulator ostarine in an orchiectomized rat model.使用选择性雄激素受体调节剂奥沙利肽治疗去势大鼠骨质疏松症。
Endocrine. 2023 Sep;81(3):579-591. doi: 10.1007/s12020-023-03422-7. Epub 2023 Jun 28.
6
Androgen Receptor Is a Non-canonical Inhibitor of Wild-Type and Mutant Estrogen Receptors in Hormone Receptor-Positive Breast Cancers.雄激素受体是激素受体阳性乳腺癌中野生型和突变型雌激素受体的非典型抑制剂。
iScience. 2019 Nov 22;21:341-358. doi: 10.1016/j.isci.2019.10.038. Epub 2019 Oct 23.
7
Targeting the Muscle-Bone Unit: Filling Two Needs with One Deed in the Treatment of Duchenne Muscular Dystrophy.靶向肌肉-骨骼单位:用一种方法治疗杜氏肌营养不良症,满足两种需求。
Curr Osteoporos Rep. 2018 Oct;16(5):541-553. doi: 10.1007/s11914-018-0468-2.
8
Evaluation of ostarine as a selective androgen receptor modulator in a rat model of postmenopausal osteoporosis.评估奥沙利肽作为绝经后骨质疏松症大鼠模型中的选择性雄激素受体调节剂。
J Bone Miner Metab. 2019 Mar;37(2):243-255. doi: 10.1007/s00774-018-0929-9. Epub 2018 May 21.
9
Androgen receptor agonists increase lean mass, improve cardiopulmonary functions and extend survival in preclinical models of Duchenne muscular dystrophy.雄激素受体激动剂可增加瘦体重,改善心肺功能,并延长杜氏肌营养不良症临床前模型的生存期。
Hum Mol Genet. 2017 Jul 1;26(13):2526-2540. doi: 10.1093/hmg/ddx150.
10
Local delivery of a selective androgen receptor modulator failed as an anabolic agent in a rat bone marrow ablation model.在大鼠骨髓消融模型中,局部递送选择性雄激素受体调节剂作为一种合成代谢剂未取得成功。
Acta Orthop. 2015;86(6):751-9. doi: 10.3109/17453674.2015.1074840. Epub 2015 Jul 22.
Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis.
新型非甾体选择性雄激素受体调节剂(SARM)S-40503在骨质疏松大鼠模型中的骨合成代谢作用
Biol Pharm Bull. 2003 Nov;26(11):1563-9. doi: 10.1248/bpb.26.1563.
4
New anabolic therapies in osteoporosis.
Endocrinol Metab Clin North Am. 2003 Mar;32(1):285-307. doi: 10.1016/s0889-8529(02)00056-7.
5
Pharmacodynamics of selective androgen receptor modulators.选择性雄激素受体调节剂的药效学
J Pharmacol Exp Ther. 2003 Mar;304(3):1334-40. doi: 10.1124/jpet.102.040840.
6
Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor.用于雄激素受体结合和激活的非甾体配体的关键结构特征。
Mol Pharmacol. 2003 Jan;63(1):211-23. doi: 10.1124/mol.63.1.211.
7
Maintenance of cancellous bone in ovariectomized, human parathyroid hormone [hPTH(1-84)]-treated rats by estrogen, risedronate, or reduced hPTH.雌激素、利塞膦酸盐或降低剂量的人甲状旁腺激素 [hPTH(1-84)] 对去卵巢大鼠松质骨的维持作用
Bone. 2001 Oct;29(4):352-60. doi: 10.1016/s8756-3282(01)00582-8.
8
Maintenance of vertebral body bone mass and strength created by human parathyroid hormone treatment in ovariectomized rats.人甲状旁腺激素治疗对去卵巢大鼠椎体骨量及骨强度的维持作用
Bone. 2001 Apr;28(4):414-22. doi: 10.1016/s8756-3282(01)00408-2.
9
Maintenance of cortical bone in human parathyroid hormone(1-84)-treated ovariectomized rats.人甲状旁腺激素(1-84)治疗去卵巢大鼠皮质骨的维持情况
Bone. 2001 Mar;28(3):251-60. doi: 10.1016/s8756-3282(00)00446-4.
10
Androgens and osteoporosis.雄激素与骨质疏松症。
Andrologia. 2000 May;32(3):125-30. doi: 10.1046/j.1439-0272.2000.00333.x.